Industry
Biotechnology
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
July 29, 2024 | 1:46 pm
Portfolio Pulse from Benzinga Newsdesk
July 29, 2024 | 12:22 pm
Portfolio Pulse from Benzinga Newsdesk
July 29, 2024 | 9:04 am
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 12:04 pm
Portfolio Pulse from Benzinga Insights
May 22, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
May 21, 2024 | 12:05 pm
Portfolio Pulse from Avi Kapoor
May 10, 2024 | 12:44 pm
Portfolio Pulse from Benzinga Newsdesk
April 09, 2024 | 3:36 pm
Portfolio Pulse from Benzinga Newsdesk
April 05, 2024 | 12:00 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.